指南与共识头颈部肿瘤放疗放疗物理与技术

关于空间分割放射治疗前瞻性临床转化试验设计的国际共识

An International Consensus on the Design of Prospective Clinical-Translational Trials in Spatially Fractionated Radiation Therapy.
指南 / 共识 · Adv Radiat Oncol · 2021-12-11

该国际共识针对空间分割放射治疗(SFRT)缺乏前瞻性多机构临床试验、技术与剂量参数不统一的问题,通过头颈癌和软组织肉瘤的疾病特异性专家组、迭代适宜性排序投票、专家小组共识评审与讨论及公开征求意见,为每个瘤种制定了22类试验设计标准(共163条),并给出了最终推荐及同意程度。

要点

  • 共识为晚期头颈癌和软组织肉瘤的SFRT前瞻性多机构临床试验制定了设计标准。
  • 每个瘤种形成22类试验设计标准(共163条),最终共识总体为高度至中度一致。
  • 统一晚期大体积病变患者队列、标准化SFRT技术与剂量学及物理参数、收集转化研究相关数据被认为是试验设计的关键。

核心结论

  • 该共识通过SFRT专家、潜在研究者和SFRT社区之间预先协调 fundamental 临床试验设计,为在晚期头颈癌和软组织肉瘤中测试SFRT的前瞻性多机构临床试验提供了设计指南。

研究设计与样本

  • 国际共识制定项目:确定具有足够SFRT试点经验的Primary肿瘤部位,设立疾病特异性专家小组,采用迭代适宜性排序投票、专家小组共识评审与讨论及公开征求意见形成共识。
  • 针对头颈癌和软组织肉瘤分别制定临床试验设计标准,每个瘤种22类试验设计标准、共163条标准。

主要发现

  • 针对头颈癌和软组织肉瘤制定了临床试验标准,每个瘤种22类试验设计标准(共163条),最终共识总体为高度至中度一致。
  • 统一晚期大体积病变患者队列、标准化SFRT技术与剂量学及物理参数、收集转化研究相关数据被认为是试验设计的关键。
  • 文中呈现并讨论了最终指南推荐及其同意程度。

关键数值与推荐

  • 临床试验设计标准涵盖入组资格、SFRT技术与操作、剂量与分次、靶区与正常组织剂量参数、全身治疗、临床试验终点及转化科学考虑。
  • 针对头颈癌和软组织肉瘤分别形成22类试验设计标准,共163条标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Spatially fractionated radiation therapy (SFRT), which delivers highly nonuniform dose distributions instead of conventionally practiced homogeneous tumor dose, has shown high rates of clinical response with minimal toxicities in large-volume primary or metastatic malignancies. However, prospective multi-institutional clinical trials in SFRT are lacking, and SFRT techniques and dose parameters remain variable. Agreement on dose prescription, technical administration, and clinical and translational design parameters for SFRT trials is essential to enable broad participation and successful accrual to rigorously test the SFRT approach. We aimed to develop a consensus for the design of multi-institutional clinical trials in SFRT, tailored to specific primary tumor sites, to help facilitate development and enhance the feasibility of such trials. METHODS AND MATERIALS: Primary tumor sites with sufficient pilot experience in SFRT were identified, and fundamental trial design questions were determined. For each tumor site, a comprehensive consensus effort was established through disease-specific expert panels. Clinical trial design criteria included eligibility, SFRT technology and technique, dose and fractionation, target- and normal-tissue dose parameters, systemic therapies, clinical trial endpoints, and translational science considerations. Iterative appropriateness rank voting, expert panel consensus reviews and discussions, and public comment posting were used for consensus development. RESULTS: Clinical trial criteria were developed for head and neck cancer and soft-tissue sarcoma. Final consensus among the 22 trial design categories each (a total of 163 criteria) was high to moderate overall. Uniform patient cohorts of advanced bulky disease, standardization of SFRT technologies and dosimetry and physics parameters, and collection of translational correlates were considered essential to trial design. Final guideline recommendations and the degree of agreement are presented and discussed. CONCLUSIONS: This consensus provides design guidelines for the development of prospective multi-institutional clinical trials testing SFRT in advanced head and neck cancer and soft-tissue sarcoma through in-advance harmonization of the fundamental clinical trial design among SFRT experts, potential investigators, and the SFRT community.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mayr NA, Snider JW, Regine WF, et al. An International Consensus on the Design of Prospective Clinical-Translational Trials in Spatially Fractionated Radiation Therapy. Adv Radiat Oncol. 2021. PMID: 35198833. doi:10.1016/j.adro.2021.100866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。